GenosisAI Healthcare Secures $3.6M Strategic Investment from JG Group to Build Human Digital Twin Health Platform

GenosisAI Healthcare, a South Korean AI healthcare company specializing in Human Digital Twin (HDT) technology, has signed a strategic investment and comprehensive business partnership agreement with JG Group, an investment-focused conglomerate managing approximately $64.7M (KRW 90 billion) in assets, for a total deal value of $3.6M (KRW 5 billion).

The investment is structured in two equal tranches: $1.8M (KRW 2.5 billion) for joint venture contributions to new business initiatives — with both parties participating on a 50/50 basis — and an additional $1.8M (KRW 2.5 billion) for development and operational costs. Full payment is due by August 31.

Under the agreement, the two companies will jointly pursue three strategic growth areas. The first is an HDT-based AI healthcare platform that integrates each individual’s genomic, proteomic, and metabolomic data — collectively known as multi-omics — to predict disease risk in real time and deliver personalized health solutions. The second is the global production and distribution of genomics-informed personalized health supplements, leveraging JG Group’s domestic and international distribution channels to expand GenosisAI’s GenoBioFit product lineup into global markets. The third is a B2B service focused on AI-driven operational optimization for healthcare institutions.

Founded in 2022, GenosisAI Healthcare has developed a hyper-personalized AI health management service built on third-generation Human Digital Twin technology, combining an individual’s genomic data, multi-omics profiles, and lifelog information into a unified platform. JG Group operates 11 domestic and international subsidiaries — including JG Mulsan, JG Financial, JG Nature, JG HOLDINGS USA, and JG International PNG — with a diversified portfolio spanning iron and lithium mining in Peru to a direct-to-consumer seafood platform.

“This partnership with JG Group will mark a decisive turning point in shifting the paradigm toward disease prediction, prevention, and personalized treatment through Human Digital Twin technology,” said Heewon Lee, CEO of GenosisAI Healthcare.

“By combining Genosys’s innovative AI healthcare technology with JG’s investment and distribution capabilities, we will build a healthcare platform that leads the Asia-Pacific market,” said Jaegoo Lee, Chairman of JG Group.

The two companies plan to launch a beta version of the platform and expand the health supplement product line in the second half of 2026, with additional plans to enter North American and Oceanian markets through collaboration with JG HOLDINGS USA and JG International PNG.